Anti-glycan antibodies as biomarkers for diagnosis and prognosis
Anti-glycan antibodies as biomarkers for diagnosis and prognosis
复制标题
DOI：
10.1191/0961203306lu2331oa
复制
发表时间：
2006-01-01
期刊：
影响因子：
2.6
通讯作者：
Dukler, A.
中科院分区：
文献类型：
--
作者：
Dotan, N.;Altstock, R. T.;Dukler, A.
聚糖（糖或碳水化合物）是红细胞、免疫细胞和微生物等细胞的主要表面成分。因此，它们会产生高水平的所有类别的抗聚糖抗体。细菌、真菌和寄生虫细胞中常见的某些特定单糖、二糖和寡糖的抗体存在于人类血清中，并且可以使用聚糖阵列进行分析。使用聚糖阵列对多发性硬化症 (MS) 和克罗恩病 (CD) 患者的血液样本与对照组的血液样本进行系统筛查，发现了一些抗聚糖抗体生物标志物，可以对 MS 和 CD 患者进行诊断和预后。抗 Gle(α 1,4)Glc(α) IgM 抗体被发现对 MS 患者具有特异性，能够区分 MS 患者和其他神经系统疾病患者，敏感性为 54%，特异性为 85%。研究发现，抗 Glc(α 1,4)Glc(α) IgM 可预测首次急性神经系统事件患者转变为临床定义的 MS。发现抗昆布二糖苷 (ALCA)、抗甘露二糖苷 (AMCA) 和抗壳二糖苷 (ACCA) 抗体具有 CD 特异性。这些抗体的联合使用能够改善 CD 与溃疡性结肠炎和其他胃肠道疾病的诊断，以及对患有更复杂疾病和高手术风险的 CD 患者进行分层。抗聚糖抗体分析（AGAP）是一种新的、有前景的诊断和预后生物标志物开发方法。
Glycans (sugars or carbohydrates) are predominant surface components of cells such as erythrocytes, immune cells and microorganisms. As such, they give rise to high levels of anti-glycan antibodies of all classes. Antibodies to certain defined mono, di and oligosaccharides that are common in bacterial, fungal and parasite cells exist in human sera and can be profiled using glycan arrays. The use of glycan arrays for systematic screening of blood samples from multiple sclerosis (MS) and Crohn's disease (CD) patients in versus to blood samples from control groups, have lead to the discovery of a few anti glycan antibodies biomarkers enabling diagnosis and prognosis in MS and CD patients. Anti-Gle(alpha 1,4)Glc(alpha) IgM antibodies were found to be specific for MS patients, enabling differentiation between MS patients and patients with other neurological diseases, with 54% sensitivity and 85% specificity. Anti-Glc(alpha 1,4)Glc(alpha) IgM were found to be predictive for the conversion of patients in first acute neurological event to clinically defined MS. Anti-laminaribioside (ALCA), anti-mannobioside (AMCA) and anti-chitobioside (ACCA) antibodies were found lobe specific for CD. The combined use of these antibodies enables improved diagnosis of CD versus ulcerative colitis and other gastrointestinal diseases, as well as stratification of CD patients with a more complicated disease and high risk for surgery. Anti-glycan antibodies profiling (AGAP) is a new and promising approach for development of biomarkers for diagnosis and prognosis.